Before starting treatment with MAVYRET, your healthcare professional will do blood tests to check for hep B infection.
You should not take MAVYRET if you are already taking atazanavir or rifampin.
See complete Important Safety Information below, including important warning about hepatitis B reactivation.
MAVYRET is a prescription medicine used to treat adults and children 3 years of age and older with chronic (lasting a long time) hepatitis C virus (hep C):
What is the most important information I should know about MAVYRET?
Hepatitis B virus (hep B) reactivation: Before starting treatment with MAVYRET, your doctor will do blood tests to check for hep B infection. If you have ever had hep B infection, hep B could become active again during or after treatment for hep C with MAVYRET. Hep B that becomes active again (called reactivation) may cause serious liver problems, including liver failure and death. Your doctor will monitor you if you are at risk for hep B reactivation during treatment and after you stop taking MAVYRET.
Do not take MAVYRET if you:
What should I tell my doctor before taking MAVYRET?
What are the possible side effects of MAVYRET?
These are not all the possible side effects of MAVYRET. Call your doctor for medical advice about side effects.
This is the most important information to know about MAVYRET. For more information, talk to your doctor or healthcare provider.
MAVYRET oral pellets are dispensed in unit-dose packets. Each packet contains 50 mg glecaprevir/20 mg pibrentasvir.
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit
or call 1-800-FDA-1088.
If you are having difficulty paying for your medicine, AbbVie may be able to help. Visit AbbVie.com/myAbbVieAssist to learn more.
US-MAVY-220155